Open AccessNovel centrosome protein, TCC52, is a cancer‐testis antigen
Author(s) -
Li Sichen,
Hu Xiaohua,
Cui Shuang,
He Dacheng
Publication year - 2008
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2008.00937.x
Subject(s) - cancer , lung cancer , antigen , prostate cancer , immunogenicity , antibody , cancer research , centrosome , biology , cancer immunotherapy , immunotherapy , medicine , pathology , immunology , cell cycle
A novel centrosome protein, TCC52, was identified as a cancer‐testis (CT) antigen. The TCC52 gene was tissue‐restricted in normal tissues but highly expressed in lung cancer tissues and some cancer cell lines. Immunoglobulin G antibody specific to TCC52 was detected in serum samples from patients with prostate cancer (59.4%, 69/116), cholangiocarcinoma (17.6%, 6/34), laryngeal cancer (8%, 8/100) and lung cancer (5.6%, 4/71) in patients, rather than from healthy donors. Based on its restricted expression pattern and immunogenicity in some types of tumor, TCC52, as a novel CT antigen, would be a promising candidate for cancer immunotherapy. ( Cancer Sci 2008; 99: 2274–2279)